Lowering of blood pressure (BP) in high-risk hypertensive individuals reduces major adverse cardiovascular (CV) events. Diabetic patients with hypertension benefit from BP lowering treatment. The present trial,IPAD in brief, is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study involving 12,000 patients to be recruited over three years and to be followed up for a median of three years and a half. IPAD tests the hypothesis that antihypertensive medications in adults with type 2 diabetes, whose seated BP 130-149 mm Hg systolic and below 90 mm Hg diastolic, results in 35% difference in the incidence of stroke. During follow-up the sitting systolic pressure should be decreased both by at least 10 mm Hg and lower than 130 mm Hg, by titration and combination of the double-blind study medications of an angiotensin type-1 receptor blocker Allisartan (240 mg/day), a dihydropyridine calcium-channel blocker (amlodipine 5-10 mg/day), and a hydrochlorothiazide (12.5-25 mg/day). In the placebo group, identical tablets will be used similarly.